Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms

IMPORTANCE: Disparities that affect Black persons with various hematological malignant neoplasms are substantial, yet little is known about disparities related to the use of US Food and Drug Administration (FDA)–approved chimeric antigen receptor–T cell (CAR-T) therapy. OBJECTIVE: To examine the enr...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Hadidi, Samer, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, van Rhee, Frits
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021907/
https://www.ncbi.nlm.nih.gov/pubmed/35442451
http://dx.doi.org/10.1001/jamanetworkopen.2022.8161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021907/
https://www.ncbi.nlm.nih.gov/pubmed/35442451
http://dx.doi.org/10.1001/jamanetworkopen.2022.8161

Ejemplares similares